Minidiab (Glipizide)

Glipizide, the active ingredient in Minidiab, is a sulfonylurea presented as a tablet for oral use. It treats type 2 diabetes mellitus by stimulating insulin release in adult patients. GNH USA supplies Minidiab as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Glipizide is used in the management of type 2 diabetes mellitus, a disorder of glucose metabolism. - Type 2 diabetes mellitus: improves overall glycemic control by increasing endogenous insulin secretion. - Hyperglycemia associated with type 2 diabetes: lowers fasting and post‑prandial blood glucose levels. - Adjunct to diet and exercise in type 2 diabetes: helps achieve target HbA1c when lifestyle measures alone are insufficient.

Glipizide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hypoglycemia: feeling of shakiness, sweating, or confusion due to low blood sugar. - Weight gain: modest increase in body weight during therapy. - Nausea: mild stomach upset or queasiness. - Headache: occasional mild to moderate head pain.

Serious or Rare Side Effects: - Severe hypoglycemia: prolonged low blood glucose requiring medical attention. - Allergic reactions: rash, itching, or swelling that may indicate hypersensitivity. - Hematologic abnormalities: rare cases of leukopenia or thrombocytopenia.

Before initiating glipizide therapy, several safety considerations should be observed. - Blood glucose monitoring: regularly check glucose levels to avoid hypoglycemia. - Renal impairment: dose may need adjustment in patients with reduced kidney function. - Elderly patients: start with a lower dose and monitor closely for adverse effects. - Sulfonylurea allergy: discontinue if signs of hypersensitivity appear. - Concomitant hypoglycemic agents: avoid combining with other insulin‑secretagogues without medical supervision. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Glipizide can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Insulin or other sulfonylureas: additive risk of severe hypoglycemia. - CYP2C9 inhibitors (e.g., fluconazole, amiodarone): increase glipizide plasma concentrations. - Alcohol: may potentiate hypoglycemic effect.

Moderate Interactions (Monitor Closely): - Warfarin: glipizide may enhance anticoagulant effect, requiring INR monitoring. - Beta‑blockers: may mask hypoglycemia symptoms, necessitating closer glucose surveillance.